Dupilumab (Dupixent) has been approved to treat eosinophilic esophagitis in adults and children ages 12 years and older who weigh at least 40 kilograms. This is the first drug approved to treat this disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NAJ.0000874100.31418.5d | DOI Listing |
Publication Analysis
Top Keywords
approved treat
8
indication dupilumab
4
dupilumab dupilumab
4
dupilumab dupixent
4
dupixent approved
4
treat eosinophilic
4
eosinophilic esophagitis
4
esophagitis adults
4
adults children
4
children ages
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!